Skip to main content

Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment

Cancer Chemotherapy and Pharmacology volume 68, pages 1459–1467 (2011)Cite this article

Abstract

Purpose

To investigate resveratrol (RSV) as a calorie restriction (CR) mimetic potentiator of platinum-based cancer drugs.

Methods

In ovarian carcinoma cell lines, the potentiating effects of RSV were assessed in sulforhodamine B-based growth assays and clonogenic assays. Flow cytometry was used to detect cell cycle effects, siRNA transfections for determining the involvement of SIRT1, and Western blotting for the assessment of altered protein expression and of autophagy. Intracellular ATP levels were detected with a commercial kit.

Results

Single-dose RSV co-treatment with cisplatin or carboplatin at inefficiently low doses had the clinically interesting effect of preventing regrowth of cancer cells after drug withdrawal. Of three cell lines tested, metastatic cells with low bioenergetic cellular index (i.e., more glycolytic) were particularly sensitive to combination treatment leading to PUMA induction, acute apoptosis, and autophagy. However, inhibition of regrowth and complete loss of clonogenicity was seen also without these events, in other cells. The underlying mechanism(s) was independent of effects reported to underlie the CR-mimetic cancer-preventive potential of RSV. Thus, SIRT1, estrogen receptors, AMPK activation or upregulation of mitobiogenesis, β-F1-ATPase or PTEN were not involved, and ATP levels did not decrease.

Conclusions

RSV is an excellent candidate for potentiation of platinum treatment, rather than a cancer therapeutic drug in its own right. While SIRT1-dependent and lifespan-promoting effects of RSV are well-documented and may dominate in normal cells, the observed potentiation of platinum drugs does not require these mechanisms. We suggest that the responses of cancer cells to RSV differ greatly from those of normal cells.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL (2009) Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486:95–102

    PubMed  Article  CAS  Google Scholar 

  2. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74:619–624

    PubMed  Article  CAS  Google Scholar 

  3. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA (2007) Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28:282–293

    PubMed  Article  CAS  Google Scholar 

  4. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, Fernandez-Salguero PM (2007) Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 96:1595–1604

    PubMed  Article  CAS  Google Scholar 

  5. Bishayee A (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila Pa) 2:409–418

    Article  CAS  Google Scholar 

  6. Brisdelli F, D’Andrea G, Bozzi A (2009) Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10:530–546

    PubMed  CAS  Google Scholar 

  7. Brooks CL, Gu W (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9:123–128

    PubMed  Article  CAS  Google Scholar 

  8. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I (2010) Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch Biochem Biophys

  9. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC (2002) The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 62:6674–6681

    PubMed  CAS  Google Scholar 

  10. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9:447–464

    PubMed  Article  CAS  Google Scholar 

  11. Gledhill JR, Montgomery MG, Leslie AG, Walker JE (2007) Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA 104:13632–13637

    PubMed  Article  CAS  Google Scholar 

  12. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M (2009) Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-d-glucose treatment. Mol Cancer Ther 8:1916–1923

    PubMed  Article  CAS  Google Scholar 

  13. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M, Reed JC, Cuezva JM (2004) Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 378:17–20

    PubMed  Article  CAS  Google Scholar 

  14. Klinge CM (2008) Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 105:1342–1351

    PubMed  Article  CAS  Google Scholar 

  15. Kueck A, Opipari AW Jr, Griffith KA, Tan L, Choi M, Huang J, Wahl H, Liu JR (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 107:450–457

    PubMed  Article  CAS  Google Scholar 

  16. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122

    PubMed  Article  CAS  Google Scholar 

  17. Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26:995–1005

    PubMed  Article  Google Scholar 

  18. Lin CS, Wang LS, Tsai CM, Wei YH (2008) Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. Interact Cardiovasc Thorac Surg 7:954–958

    PubMed  Article  Google Scholar 

  19. Lin PC, Lin JK, Yang SH, Wang HS, Li AF, Chang SC (2008) Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis 23:1223–1232

    PubMed  Article  Google Scholar 

  20. Majewski N, Nogueira V, Robey RB, Hay N (2004) Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 24:730–740

    PubMed  Article  CAS  Google Scholar 

  21. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2010) Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9:1057–1064

    PubMed  Article  CAS  Google Scholar 

  22. Mizushima N, Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3:542–545

    PubMed  CAS  Google Scholar 

  23. Morselli E, Galluzzi L, Kepp O, Criollo A, Maiuri MC, Tavernarakis N, Madeo F, Kroemer G (2009) Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY) 1:961–970

    CAS  Google Scholar 

  24. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G (2010) The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy 6:186–188

    PubMed  Article  Google Scholar 

  25. Pizarro JG, Verdaguer E, Ancrenaz V, Junyent F, Sureda F, Pallas M, Folch J, Camins A (2011) Resveratrol inhibits proliferation and promotes apoptosis of neuroblastoma cells: role of sirtuin 1. Neurochem Res 36:187–194

    PubMed  Article  CAS  Google Scholar 

  26. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, Auberger P (2010) Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70:1042–1052

    PubMed  Article  CAS  Google Scholar 

  27. Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, Inoue M (2005) Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol 289:C1466–C1475

    PubMed  Article  CAS  Google Scholar 

  28. Sanchez-Arago M, Chamorro M, Cuezva JM (2010) Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 31:567–576

    PubMed  Article  CAS  Google Scholar 

  29. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598–608

    PubMed  Article  CAS  Google Scholar 

  30. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG (2005) Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65:3162–3170

    PubMed  CAS  Google Scholar 

  31. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P (2010) Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol

  32. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R (2005) Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26:1978–1987

    PubMed  Article  CAS  Google Scholar 

  33. Ventura-Clapier R, Garnier A, Veksler V (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 79:208–217

    PubMed  Article  CAS  Google Scholar 

  34. Waite KA, Sinden MR, Eng C (2005) Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet 14:1457–1463

    PubMed  Article  CAS  Google Scholar 

  35. White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 15:5308–5316

    PubMed  Article  Google Scholar 

  36. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52:4196–4199

    PubMed  CAS  Google Scholar 

  37. Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH (2009) PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ 16:1135–1145

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Swedish Cancer Society, Radiumhemmet Research Foundation, Olle Engkvist Byggmästare and Sigurd and Elsa Golje Foundations. Linnéa Björklund is gratefully acknowledged for photography, and Drs. Theocharis Panaretakis and Pedram Kharaziha for technical advice.

Conflict of interest

None.

Author information

Affiliations

  1. Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, 171 76, Stockholm, Sweden

    My Björklund, Jeanette Roos & Maria Shoshan

  2. Institute of Environmental Medicine (IMM), Karolinska Institutet, 171 77, Stockholm, Sweden

    Vladimir Gogvadze

Authors
  1. My Björklund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeanette Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vladimir Gogvadze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Shoshan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Shoshan.

Additional information

M. Björklund and J. Roos equally contributed to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 48400 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Björklund, M., Roos, J., Gogvadze, V. et al. Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol 68, 1459–1467 (2011). https://doi.org/10.1007/s00280-011-1640-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1640-x

Keywords

  • Chemotherapy
  • Platinum
  • Resveratrol
  • SIRT1
  • Ovarian carcinoma